Lucidenic acid A inhibits the binding of hACE2 receptor with spike protein to prevent SARS-CoV-2 invasion

Xu, Juan; Yang, Wentao; Pan, Yunlong; Xu, Haishun; Li, He; Zheng, Bingsong; Xie, Yingqiu; Wu, Xue‐Qian

doi:10.1016/j.fct.2022.113438

Cited by 6 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the efficacy of anti-viral medications decreased with the appearance of new SARS-CoV-2 variants [ 10 ], blocking hACE2 may be an effective method to prevent SARS-CoV-2 infection [ 10 ]. The molecular docking results showed that lucidenic acid A has good binding stability to hACE2 (interaction with the amino acid residues Gln96, Asn33 and Lys26) [ 61 ]. In vitro fluorescence resonance energy transfer tests also demonstrated that lucidenic acid A inhibited hACE2 with an IC 50 of 2 μmol/mL [ 61 ].…”

Section: Potential Pharmacological Effects Of Lucidenic Acidsmentioning

confidence: 99%

“…The molecular docking results showed that lucidenic acid A has good binding stability to hACE2 (interaction with the amino acid residues Gln96, Asn33 and Lys26) [ 61 ]. In vitro fluorescence resonance energy transfer tests also demonstrated that lucidenic acid A inhibited hACE2 with an IC 50 of 2 μmol/mL [ 61 ]. This suggests that lucidenic acids may be useful for the prevention or treatment of COVID-19.…”

Section: Potential Pharmacological Effects Of Lucidenic Acidsmentioning

confidence: 99%

See 1 more Smart Citation

A Review on the Sources, Structures, and Pharmacological Activities of Lucidenic Acids

et al. 2023

View full text Add to dashboard Cite

Ganoderma lucidum has long been used as a multi-purpose plant and functional food. The pharmacological properties of G. lucidum are primarily attributed to its polysaccharides and triterpenoids. Ganoderic and lucidenic acids are the two major triterpenoids groups in G. lucidum. Despite the discovery of 22 types of lucidenic acids, research on lucidenic acids is significantly less extensive compared to that on ganoderic acid. To the best of our knowledge, for the first time, in this review, we aimed to summarize the sources, contents, chemical structures, and pharmacological effects, including anti-cancer, anti-inflammatory, antioxidant, anti-viral, neuroprotective, anti-hyperlipidemic, anti-hypercholesterolemic, and anti-diabetic properties, of lucidenic acids. Studies on lucidenic acids are still preliminary and have several limitations. Therefore, more in-depth studies with optimal designs are essential for the development of lucidenic acids as medicines, functional foods, and nutraceuticals.

show abstract